ArticleMedicine2026
Prostate cancer and diabetes: A retrospective analysis of mortality trends in the United States (1999-2024).
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a prevalent comorbid condition that can influence the progression of prostate cancer, which remains one of the leading malignancies among men in the United States. Knowing the long-term mortality trends in this high-risk population is essential for developing care, early diagnosis, and prevention plans. Using surveillance data from the Centers for Disease Control and Prevention, we evaluated how prostate cancer mortality among diabetic United States adults has changed over the 25 years between 1999 and 2024. International Classification of Diseases, 10th Revision codes for prostate cancer (C61) and diabetes (E10-E14) were utilized to examine mortality trends. Deaths were counted when prostate cancer was listed as the underlying cause and diabetes was listed as a contributing cause of death. We analyzed race, urban/rural, state, and census region-wise mortality trends. Joinpoint (V5.4.0) was used to analyze trends. Across 1999 to 2024, male age-adjusted mortality rates showed a fluctuating but overall stable pattern, with an initial significant decline, a marked rise after 2017, and a subsequent nonsignificant decrease, resulting in no significant long-term trend (average annual percent change = -0.41). Racial disparities were consistent, with non-Hispanic (NH) Black individuals experiencing the highest mortality rates, followed by NH Whites and Hispanics, while other groups remained stable. Urban and rural trends showed parallel temporal fluctuations, with higher rates in rural areas but no sustained long-term differences. Considerable heterogeneity was observed across states and census regions, with the West showing a significant upward trend overall. These findings warrant better, more targeted interventions that should prevent and control the deaths of prostate cancer in diabetic adults with a focus on the NH Black or African American populations and areas that are experiencing more deaths.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.